Omalizumab biosimilar is under clinical development by Mabpharm and currently in Phase III for Chronic Urticaria Or Hives. According to GlobalData, Phase III drugs for Chronic Urticaria Or Hives have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Omalizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Omalizumab biosimilar overview

Omalizumab (Omalizumab Alfa) is humanized IgG1k monoclonal antibody. It is formulated as lyophilized powder for solution for subcutaneous route of administration. Omalizumab Alfa is indicated for the treatment of allergic asthma.

Omalizumab biosimilar is under development for the treatment of chronic urticaria. The drug candidate is administered through subcutaneous route. It acts by targeting immunoglobulin E (IgE).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It was under development for the treatment of allergic asthma.

Mabpharm overview

Mabpharm is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its product comprises of monoclonal antibody drugs and strong antibody drug. Its product pipeline includes CMAB008, a drug for the treatment of rheumatoid arthritis; CMAB007, a drug for treatment of asthma and CMAB009, a drug for treatment of metastatic colorectal cancer. Mabpharm collaborates with Kexing Biopharm for the promotion and distribution of its products. The company has manufacturing facilities in Taizhou, Jiangsu Province, China. It operates in mainland China and overseas market. Mabpharm is headquartered in Taizhou, Jiangsu, China.

For a complete picture of Omalizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.